Prednisone

Generic Name: Prednisone

Brand Names: Deltasone, Rayos, Winpred

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₆O_₅

CAS Number: 53-03-2

Unique Ingredient Identifier: VB0R961HZT

Background: A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver.

Prednisone was granted FDA approval on 21 February 1955.

Indication: Prednisone is indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant.

Associated Conditions: Acne Vulgaris, Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Acute Gouty Arthritis, Acute Leukemia, Aggressive Lymphoma, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Rhinitis (AR), Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Autoimmune Hepatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Chorioretinitis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Disseminated tuberculosis, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Giant Cell Arteritis (GCA), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Iridocyclitis, Iritis, Keratitis, Leukemias, Loeffler's syndrome, Lymphoma, Meningitis caused by Mycobacterium Tuberculosis, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Pain caused by Herpes zoster, Pemphigus, Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Polymyositis, Posterior Uveitis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Regional Enteritis, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Sjogren's Syndrome (SS), Solid Organ Transplant Rejection, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Thyroid Eye Disease, Thyroiditis, Thyrotoxicosis, Trichinosis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Crohn's Disease (CD), Acute Multiple sclerosis exacerbation, Acute rheumatic carditis, Anterior eye segment inflammation, Exfoliative erythroderma, Fulminating Tuberculosis, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Psoriasis, Subacute Bursitis, Symptomatic Sarcoidosis, Synovitis of osteoarthritis, Systemic Dermatomyositis, Varicella-zoster virus acute retinal necrosis

Associated Therapies: Palliative Treatment

Clinical Trials

Prednisone in Cystic Fibrosis Pulmonary Exacerbations

Phase 3

Completed

Conditions: Cystic Fibrosis Pulmonary Exacerbation

Interventions: Drug: Placebos
Drug: Prednisone

First Posted Date: 2017-03-03

Last Posted Date: 2024-07-01

Lead Sponsor: The Hospital for Sick Children

Target Recruit Count: 76

Registration Number: NCT03070522

Locations: 🇨🇦
The Ottawa Hospital, Ottawa, Ontario, Canada
🇨🇦
The Governers of The University of Calgary - Alberta Health Services, Calgary, Alberta, Canada
🇨🇦
British Columbia Children's Hospital, Vancouver, British Columbia, Canada

and more 9 locations

Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas

Phase 1

Completed

Conditions: Diffuse Large B-Cell Lymphoma
High Grade B-Cell Lymphoma

Interventions: Drug: Venetoclax
Drug: Rituximab
Drug: Etoposide
Drug: Vincristine Sulfate
Drug: Cyclophosphamide
Drug: Prednisone
Drug: Doxorubicin Hydrochloride

First Posted Date: 2017-01-30

Last Posted Date: 2022-08-24

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 31

Registration Number: NCT03036904

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

and more 3 locations

Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients

Phase 3

Conditions: Peripheral T Cell Lymphoma

Interventions: Drug: chidamide
Drug: cyclophosphamide
Drug: liposomal doxorubicin
Drug: vincristine
Drug: prednisone

First Posted Date: 2017-01-18

Last Posted Date: 2017-01-18

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 174

Registration Number: NCT03023358

Locations: 🇨🇳
Ru Feng, Guangzhou, Guangdong, China

Pharmacogenomics of the Variability in the In Vivo Response to Glucocorticoids

Phase 1

Completed

Conditions: Glucose Intolerance
Glucocorticoids Toxicity

Interventions: Drug: Prednisone

First Posted Date: 2017-01-18

Last Posted Date: 2020-06-04

Lead Sponsor: Vanderbilt University Medical Center

Target Recruit Count: 25

Registration Number: NCT03023891

Locations: 🇺🇸
Vanderbilt University Medical Center -CRC, Nashville, Tennessee, United States

Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Phase 2

Completed

Conditions: Acute Lymphoblastic Leukemia
Lymphoblastic Lymphoma

Interventions: Drug: Cyclophosphamide
Drug: Dasatinib
Drug: Doxorubicin
Drug: Etoposide
Drug: Imatinib Mesylate
Other: Laboratory Biomarker Analysis
Drug: Prednisone
Biological: Rituximab
Drug: Vincristine Sulfate

First Posted Date: 2017-01-18

Last Posted Date: 2022-07-13

Lead Sponsor: University of Washington

Target Recruit Count: 54

Registration Number: NCT03023046

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

R-ACVBP and DA-EPOCH-R in Patients With Non-GCB DLBCL

Phase 3

Conditions: Lymphoma, Large B-Cell, Diffuse

Interventions: Drug: Rituximab
Drug: Etoposide
Drug: Doxorubicin
Drug: Vincristine
Drug: Cyclophosphamide
Drug: Vindesine
Drug: Bleomycin
Drug: Prednisone

First Posted Date: 2017-01-12

Last Posted Date: 2017-07-28

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 402

Registration Number: NCT03018626

Locations: 🇨🇳
Ru Feng, Guangzhou, Guangdong, China

Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer

Phase 4

Conditions: Castration-Resistant Prostatic Cancer
Stage IV Prostate Cancer
Hormone-Refractory Prostate Cancer
Recurrent Prostate Carcinoma
Metastatic Prostate Carcinoma

Interventions: Biological: GnRH agonist/antagonist
Drug: Enzalutamide
Drug: Prednisone
Drug: Abiraterone Acetate

First Posted Date: 2017-01-11

Last Posted Date: 2021-05-03

Lead Sponsor: Northwestern University

Target Recruit Count: 100

Registration Number: NCT03016741

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
University of Minnesota: Masonic Cancer Center, Minneapolis, Minnesota, United States

and more 1 locations

Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects

Phase 2

Active, not recruiting

Conditions: Prostate Cancer Metastatic Castration-Resistant
Metastatic Prostate Carcinoma
Abnormal DNA Repair
Stage IV Prostate Cancer

Interventions: Drug: Olaparib
Drug: Abiraterone Acetate
Drug: Prednisone

First Posted Date: 2017-01-06

Last Posted Date: 2023-08-30

Lead Sponsor: Northwestern University

Target Recruit Count: 70

Registration Number: NCT03012321

Locations: 🇺🇸
Weill Cornell Medical College, New York, New York, United States
🇺🇸
University of Virginia, Charlottesville, Virginia, United States
🇺🇸
Northwestern Medicine, Chicago, Illinois, United States

and more 15 locations

A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer

Phase 3

Active, not recruiting

Conditions: Prostate Cancer

Interventions: Drug: Apalutamide
Drug: LHRH Analogue
Drug: Abiraterone Acetate
Drug: Prednisone

First Posted Date: 2017-01-04

Last Posted Date: 2024-08-07

Lead Sponsor: Alliance Foundation Trials, LLC.

Target Recruit Count: 504

Registration Number: NCT03009981

Locations: 🇺🇸
Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸
Atlantic Health System/Morristown Medical Center, Morristown, New Jersey, United States
🇺🇸
The Toledo Clinic, Toledo, Ohio, United States

and more 52 locations

Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT

Phase 2

Active, not recruiting

Conditions: Prostatic Neoplasms

Interventions: Drug: Pembrolizumab
Drug: SD-101
Drug: Leuprolide acetate
Drug: Abiraterone Acetate
Drug: Prednisone
Radiation: Stereotactic Body Radiation Therapy

First Posted Date: 2017-01-02

Last Posted Date: 2024-12-06

Lead Sponsor: David Oh

Target Recruit Count: 23

Registration Number: NCT03007732

Locations: 🇺🇸
University of California San Francisco, San Francisco, California, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy